It Will Take Your Breath Away: A Case of Rapidly Progressing Pulmonary Tumor Thrombotic Microangiopathy (PTTM) in the Setting of Metastatic Breast Cancer

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 678A
Author(s):  
Akash Sethi ◽  
Badrish Patel
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Thrombotic Microangiopathy ◽  
Metastatic Breast ◽  
Pulmonary Tumor ◽  
Pulmonary Tumor Thrombotic Microangiopathy

scholarly journals Acute cor pulmonale due to pulmonary tumor thrombotic microangiopathy in two patients with breast cancer

2017 ◽  
Vol 32 (1) ◽  
pp. 190-194 ◽  
Author(s):  
Sung Young Moon ◽  
Kang Hoon Lee ◽  
Jong Sik Lee ◽  
Hyun Suk Yang ◽  
Hong Ghi Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Thrombotic Microangiopathy ◽  
Cor Pulmonale ◽  
Acute Cor Pulmonale ◽  
Pulmonary Tumor ◽  
Pulmonary Tumor Thrombotic Microangiopathy

scholarly journals Pulmonary Tumor Thrombotic Microangiopathy (PTTM) Caused by Breast Cancer—A Case Report—

2017 ◽  
Vol 78 (4) ◽  
pp. 669-672
Author(s):  
Kaoru KIDATE ◽  
Hiroki KITAGAWA ◽  
Mahito FUNAKOSHI ◽  
Mayumi KANEKO ◽  
Chiaki ONO ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Thrombotic Microangiopathy ◽  
Pulmonary Tumor ◽  
Pulmonary Tumor Thrombotic Microangiopathy

scholarly journals The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

2016 ◽  
Vol 9 (1) ◽  
pp. 68-75 ◽  
Author(s):  
Corey A. Carter ◽  
Robert Browning ◽  
Bryan T. Oronsky ◽  
Jan J. Scicinski ◽  
Christina Brzezniak
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Paraneoplastic Syndrome ◽  
Thrombotic Microangiopathy ◽  
Anticancer Agent ◽  
Triple Negative ◽  
Due Diligence ◽  
Review Of The Literature ◽  
Pulmonary Tumor ◽  
Pulmonary Tumor Thrombotic Microangiopathy

A case report of a 47-year-old woman with triple-negative breast cancer on a clinical trial called PRIMETIME (NCT02518958) who received the anti-PD-1 inhibitor nivolumab and the experimental anticancer agent RRx-001 is presented. Although initially diagnosed and treated for anti-PD-1-induced pneumonitis, clinical and radiological abnormalities triggered further investigation, leading to the diagnosis of pulmonary tumor thrombotic microangiopathy (PTTM). This example highlights the importance of exercising due diligence in determining immune-related adverse events and suggests that PD-1-induced pneumonitis should be a diagnosis of exclusion rather than a diagnosis by default. A case history and review of the literature are presented for PTTM, which we propose to define as a paraneoplastic syndrome.

Sign in / Sign up

Export Citation Format

Share Document